Gram-Positive Bacterial Infections  >>  GC1109  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GC1109 / GC Biopharma
NCT01867957: Efficacy and Safety of Anthrax Vaccine, GC1109

Completed
1
20
RoW
Low-dose GC1109, GC1109 50ug/dose (0.5 ml) vaccination, High-dose GC1109, GC1109 100ug/dose (1.0 ml) vaccination, Low-dose Placebo, 0.9% Saline 0.5 mL vaccination, High-dose Placebo, 0.9% Saline 1.0 mL vaccination
Seoul National University Hospital, Green Cross Corporation, LSK Global Pharma Services Co. Ltd.
Anthrax
12/09
12/09

Download Options